spacer
home > ebr > spring 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

Proteins, proteins, proteins. They are a main feature in our spring edition of EBR – perhaps not surprisingly, considering the continued increase in adoption to clinical practice of high-value, high-performing protein therapeutics and the need for their manufacture at scale by the biopharmaceutical industry.

Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab would argue that, considering the market size and recent numbers of US and European approvals in these drug classes, the future for mid-size contract development and manufacturing organisations lies in complex proteins or ‘modern biopharmaceuticals’; monoclonal antibodies and proteins for cancer and autoimmune conditions in particular (see full pdf). In their articles, Christian Loch from AVMBioMed (see full pdf) and Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye (see full pdf) agree that, at present, proteomics is the best means for capturing this vital information.

AVMBioMed highlight the need to consider the importance of post-translational modification in defining the human protein repertoire, and the Trinean team plus Kris Gavaert and Francis Impens flag the need for further improvements in quality to move proteomics towards a unified regulatory process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Exploristics present the Welcome Organisation with Christmas Shoeboxes


More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

BioPharm America™ 2017—10th Annual International Partnering Conference

26-27 September 2017, 39 Dalton Street, Boston, MA 02116

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement